BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DB-1310 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DB-1310\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06220864-2450@assetmemo.bio
DTSTAMP:20261121T005815Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:DB-1310: Phase 1 readout est. (NCT06220864)
DESCRIPTION:DB-1310\, phase 1.\nStudy: SNV1521 in Participants With Advance
 d Solid Tumors\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/db-1310#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06220864
URL:https://assetmemo.bio/drug/db-1310#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785741-2450@assetmemo.bio
DTSTAMP:20261121T005815Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:DB-1310: Phase 1/2 readout est. (NCT05785741)
DESCRIPTION:DB-1310\, phase 1/2.\nStudy: A Study of DB-1310 in Advanced/Met
 astatic Solid Tumors\nEstimated primary completion: 30 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/db-1310#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05785741
URL:https://assetmemo.bio/drug/db-1310#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
